Post 5-alpha-reductase inhibitors treatment syndrome Advocacy Hub | UniteRare

At a Glance

Live from database

💊

1FDA treatments

💰

1Open funds

Regulatory Watchboard

2 events

Mar 2026DAYBUE: New indication approved

FDAcompleted

Mar 2023Daybue: FDA approved

treatment of Rett syndrome in adults and pediatric patients 2 years of age and older

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Copay cards

Copay Assistance1

Daybue

Acadia Pharmaceuticals Inc.

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

MAVYRET

(glecaprevir and pibrentasvir)Orphan drugstandard

AbbVie, Inc.

Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]

12.1 Mechanism of Action Mechanism of Action MAVYRET is a fixed-dose combination of glecaprevir and pibrentasvir, which are direct-acting antiviral ag...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Post 5-alpha-reductase inhibitors treatment syndrome.
Search all trials →

Search clinical trials for Post 5-alpha-reductase inhibitors treatment syndrome →

Recent News & Research

No recent news articles indexed yet for Post 5-alpha-reductase inhibitors treatment syndrome.
Search PubMed for Post 5-alpha-reductase inhibitors treatment syndrome →

Browse all Post 5-alpha-reductase inhibitors treatment syndrome news →

Specialist Network

No specialists currently listed for Post 5-alpha-reductase inhibitors treatment syndrome.

View all Post 5-alpha-reductase inhibitors treatment syndrome specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰